1. Home
  2. NNY vs DTIL Comparison

NNY vs DTIL Comparison

Compare NNY & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New York Municipal Value Fund

NNY

Nuveen New York Municipal Value Fund

HOLD

Current Price

$8.62

Market Cap

163.4M

Sector

Finance

ML Signal

HOLD

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

HOLD

Current Price

$6.66

Market Cap

185.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNY
DTIL
Founded
1987
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.4M
185.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NNY
DTIL
Price
$8.62
$6.66
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$45.00
AVG Volume (30 Days)
25.1K
350.8K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
4.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,070,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.93
$3.53
52 Week High
$8.94
$8.82

Technical Indicators

Market Signals
Indicator
NNY
DTIL
Relative Strength Index (RSI) 60.70 51.22
Support Level $8.47 $6.30
Resistance Level $8.74 $7.96
Average True Range (ATR) 0.11 0.57
MACD 0.01 0.01
Stochastic Oscillator 68.75 41.97

Price Performance

Historical Comparison
NNY
DTIL

About NNY Nuveen New York Municipal Value Fund

Nuveen New York Municipal Value Fund Inc. is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Share on Social Networks: